I’ve Plateaued on Retatrutide. What Now?

Overview

It happened somewhere around week six or eight. The first stretch on Retatrutide was almost easy: the appetite went quiet, the scale moved every few days, the clothes changed. Then, without you changing anything, it stopped. Same dose, same routine, the same number for two weeks running. It is one of the most common messages our support team receives, and it almost always arrives with the same worry: has the peptide stopped working?

In most cases, no. The peptide is still doing its job. What has changed is the capacity of the organ that has to finish that job: your liver.

Here is the short version. Losing fat is not one step, it is two. Retatrutide handles the first: it releases stored fat and turns up how much energy your body burns. Your liver handles much of the second: the released fat has to be taken in, broken down, and burned or turned into fuel for the rest of you. When the liver keeps up, weight comes off steadily. When it falls behind, the release keeps happening but the burning does not, and the scale stops. Support the liver and, in our experience, the plateau lifts. The rest of this article explains why, and how.

Why Plateaus Happen: The Part the Textbooks Cover

Two things the research already explains well. First, your body adapts to a deficit. As weight comes off, resting energy expenditure drops below what your new size would predict, an old survival reflex called adaptive thermogenesis, and a smaller body simply needs fewer calories to run. Second, intake drifts back up. A mathematical model of dieting found that the familiar plateau around month six is largely explained by food intake creeping upward, even when people are sure nothing has changed.

Both are real, and neither is a failure, and an honest food log settles the second one quickly. But when the plate has not changed, the dose has not changed, and the scale still stops, we look somewhere else.

The Part Most Guides Leave Out: Your Liver Has to Burn What You Release

Fat does not leave your body from the place it was stored. When Retatrutide signals fat cells to let go, the fat enters your blood as free fatty acids and travels to the tissues that can burn it. Your liver is the central processing plant. It takes fatty acids in, breaks them down, and converts a large share of them into ketones that feed your muscles, heart and brain. It also packages what it cannot burn and ships it back out.

Retatrutide leans on the liver harder than the older single-pathway peptides did, because its glucagon arm tells the liver to burn fat at a higher rate. That is a large part of why it works so well. In a 2024 phase 2a trial in people with fatty liver disease, the two higher Retatrutide doses cut liver fat by an average of more than 80 percent within 24 weeks. The liver is, quite literally, where much of this weight leaves.

Every step of that burning runs on NAD+, the coenzyme your mitochondria use to turn fat into usable energy. Fat loss raises NAD+ demand at exactly the moment appetite suppression cuts the food that supplies its building blocks. In mice with fatty liver, restoring NAD+ reversed the fat build-up and restarted mitochondrial fat burning. In our experience, the bottleneck behind fatigue on Retatrutide and the one behind the plateau are the same.

When the liver gets backed up, the weight loss stops. That is the big thing to know. If fat is being released faster than the liver can burn it, the surplus does not vanish; it lingers, some of it inside the liver itself, and inflammation rises. Inflammatory signaling in turn slows fat oxidation and interferes with the hormones that regulate metabolism, so the liver falls further behind. The release continues, the burning stalls, and the scale sits still. People often notice the tiredness and the flat feeling at the same time; they share a cause.

So the plateau question becomes a simpler one: what is the liver carrying, and what would let it burn more?

Step 1: Give the Liver the NAD+ It Is Burning Through

Our first recommendation is 5-Amino-1MQ. It blocks an enzyme called NNMT that sits in fat cells and in the liver and quietly consumes the building blocks your body would otherwise turn into NAD+. In research, high NNMT activity travels with obesity and fatty liver. Turning it down, in mice, protected against diet-induced weight gain and raised energy expenditure, and 5-Amino-1MQ itself reduced body weight and fat in mice on a high-fat diet without changing how much they ate.

Why we recommend 5-Amino-1MQ over supplementing NAD+ directly: we believe it is better to help your body produce its own NAD+ than to supply it from outside. When the body makes its own, it keeps the metabolic functions that come with the making. The research on NNMT ties lower activity to higher energy expenditure, better fat handling in the liver, and calmer inflammatory and fibrotic signaling, so the benefit is broader than the NAD+ number alone: more fat burned, more energy while you burn it, and less of the inflammation that backs the liver up in the first place. That combination is exactly what a plateau needs.

If you would rather take the direct route, or want both, NAD+ itself works. The Retatrutide + NAD+ bundle pairs the two in one order. Either way, when your liver is burning fat all day, it is better to have more NAD+ than less.

Our weight-loss cycles already build this in. The Slim Peptides Cycle is Retatrutide with 5-Amino-1MQ; the Prime Metabolic Cycle adds BPC-157 and TB-500 for recovery and inflammatory support on top. If you have been running Retatrutide on its own and have stalled, moving to one of these is the most direct fix we know.

Step 2: Support the Liver Itself

Livagen. It is the liver-focused peptide bioregulator, a short four-amino-acid peptide (Lys-Glu-Asp-Ala) studied in the bioregulator literature for liver-cell health, for reactivating gene expression in older cells, and for liver function in aging and injury models. It is a natural partner to either NAD+ approach above, and a good choice when the cut has been long.

Milk thistle. The best-studied herbal liver support. Research reviews describe silymarin’s antioxidant and anti-inflammatory action in the liver and its use in fatty-liver studies. We do not sell it; it is widely available, and it earns its place while your liver is processing weeks of mobilized fat.

Real food, not another restriction. A backed-up liver does not need less fuel; it needs the right fuel. Rice, meat and vegetables, in the modest portions Retatrutide allows, keep the B vitamins and minerals coming that fat burning consumes. If you have been pairing Retatrutide with strict keto, that is often part of the stall.

Step 3: Sweat Every Week: Exercise First, Sauna If You Do Not

Exercise is key, and not only for the calories. Meta-analyses of exercise in people with fatty liver found that regular training clears fat from the liver even when the scale barely moves, and that both aerobic and resistance work do it. Exercise training also lowers CRP, the standard blood marker of inflammation, over time. It is the most reliable way we know to raise the liver’s capacity rather than only its workload.

If you do not exercise, or cannot yet, use the sauna. Three sessions a week, long enough to sweat profusely, with an electrolyte drink in hand. In our experience this alone moves a stalled plateau more than almost anything else people try. The research points the same way: in the Finnish sauna cohort, more frequent sauna use went with lower CRP; passive heat therapy improved blood-vessel function in sedentary adults; and in women with obesity it improved insulin sensitivity and cardiovascular risk markers. A hard sweat asks the body for the same things exercise does, a higher heart rate, more circulation, and a drop in inflammatory signaling, which is why it helps the liver in the same direction.

Electrolytes are not optional. A single sauna session can take close to a litre of fluid out of you, and with it sodium, potassium and magnesium. Drink an electrolyte mix before, during and after, and stop the session if you feel dizzy or unwell. Sweat profusely, hydrate seriously, repeat three times a week.

Step 4: Take the Load Off

Anything that inflames the body puts pressure on the liver and slows its ability to burn fat. Anything that reduces inflammation helps. Alcohol is the clearest example. Your liver processes alcohol first, ahead of everything else; while it does, fatty-acid oxidation switches off and fat synthesis in the liver switches on. An evening of drinks is a day or two of your liver doing something other than burning your fat. While you are trying to break a plateau, take drinking off the table, or down to the rare glass.

The tools above work the same lever from the other side. 5-Amino-1MQ and a regular hard sweat both lower inflammatory signaling while they raise metabolism, which is why they sit at the top of this list. Give the liver less to clean up, more to burn with, and it gets back to the work Retatrutide is sending it.

Check the Simple Things

• Do not raise the dose to break a plateau. Pantheon research protocols hold Retatrutide at 4 mg per week or less, and in our experience a plateau is a liver-capacity problem, not a dose problem. More peptide means more fat released into a system that is already behind.
• Weigh honestly. Two weeks at the same number is a plateau. One heavy weekend is not.
• Eat enough protein and real food, sleep 7 to 9 hours, and keep the electrolytes up. These are the quiet supports the liver runs on.
• Give the changes two to three weeks. The liver recovers capacity quickly once the load comes off, but not overnight.
• If you have reached your target, the plateau may simply be the finish line. Move into a continuation cycle rather than pushing further.

Seek medical advice promptly if you notice yellowing of the skin or eyes, dark urine, or pain under the right ribs. Those are liver signals that need a clinician, not a supplement.

Read More

The full story, told the way it actually feels, is on our blog:

References

Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff et al., 2023, N Engl J Med)
Link: https://pubmed.ncbi.nlm.nih.gov/37366315/

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Sanyal et al., 2024, Nat Med)
Link: https://pubmed.ncbi.nlm.nih.gov/38858523/

Adaptive thermogenesis in humans (Rosenbaum & Leibel, 2010, Int J Obes)
Link: https://pubmed.ncbi.nlm.nih.gov/20935667/

Quantification of the effect of energy imbalance on bodyweight (Hall et al., 2011, Lancet)
Link: https://pubmed.ncbi.nlm.nih.gov/21872751/

Effect of dietary adherence on the body weight plateau: a mathematical model incorporating intermittent compliance with energy intake prescription (Thomas et al., 2014, Am J Clin Nutr)
Link: https://pubmed.ncbi.nlm.nih.gov/25080458/

Energy metabolism in the liver (Rui, 2014, Compr Physiol)
Link: https://pubmed.ncbi.nlm.nih.gov/24692138/

Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics (Puchalska & Crawford, 2017, Cell Metab)
Link: https://pubmed.ncbi.nlm.nih.gov/28178565/

Glucagon receptor signaling and lipid metabolism (Galsgaard et al., 2019, Front Physiol)
Link: https://pubmed.ncbi.nlm.nih.gov/31068828/

NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus (Cantó, Menzies & Auwerx, 2015, Cell Metab)
Link: https://pubmed.ncbi.nlm.nih.gov/26118927/

Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice (Gariani et al., 2016, Hepatology)
Link: https://pubmed.ncbi.nlm.nih.gov/26404765/

Inflammation and metabolic disorders (Hotamisligil, 2006, Nature)
Link: https://pubmed.ncbi.nlm.nih.gov/17167474/

Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Kraus et al., 2014, Nature)
Link: https://pubmed.ncbi.nlm.nih.gov/24717514/

Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization (Hong et al., 2015, Nat Med)
Link: https://pubmed.ncbi.nlm.nih.gov/26168293/

Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice (Neelakantan et al., 2018, Biochem Pharmacol)
Link: https://pubmed.ncbi.nlm.nih.gov/29155147/

Nicotinamide N-methyltransferase in non-alcoholic fatty liver disease: mechanistic insights and emerging therapeutic strategies (Zhang et al., 2025, Arch Biochem Biophys)
Link: https://pubmed.ncbi.nlm.nih.gov/40706948/

NNMT as a therapeutic target in fibrosis: insights from the heart, liver, kidneys, and lungs (Lai et al., 2026, Differentiation)
Link: https://pubmed.ncbi.nlm.nih.gov/41950636/

Anti-aging peptide bioregulators induce reactivation of chromatin (Lezhava et al., 2006, Georgian Med News)
Link: https://pubmed.ncbi.nlm.nih.gov/16705247/

The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology (Kuznik et al., 2020, Adv Gerontol)
Link: https://pubmed.ncbi.nlm.nih.gov/32362099/

Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases (Abenavoli et al., 2018, Phytother Res)
Link: https://pubmed.ncbi.nlm.nih.gov/30080294/

Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis (Keating et al., 2012, J Hepatol)
Link: https://pubmed.ncbi.nlm.nih.gov/22414768/

Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review (Hashida et al., 2017, J Hepatol)
Link: https://pubmed.ncbi.nlm.nih.gov/27639843/

Effect of exercise training on C reactive protein: a systematic review and meta-analysis of randomised and non-randomised controlled trials (Fedewa, Hathaway & Ward-Ritacco, 2017, Br J Sports Med)
Link: https://pubmed.ncbi.nlm.nih.gov/27445361/

Sauna bathing and systemic inflammation (Laukkanen & Laukkanen, 2018, Eur J Epidemiol)
Link: https://pubmed.ncbi.nlm.nih.gov/29209938/

Clinical effects of regular dry sauna bathing: a systematic review (Hussain & Cohen, 2018, Evid Based Complement Alternat Med)
Link: https://pubmed.ncbi.nlm.nih.gov/29849692/

Passive heat therapy improves endothelial function, arterial stiffness and blood pressure in sedentary humans (Brunt et al., 2016, J Physiol)
Link: https://pubmed.ncbi.nlm.nih.gov/27270841/

Heat therapy reduces sympathetic activity and improves cardiovascular risk profile in women who are obese with polycystic ovary syndrome (Ely et al., 2019, Am J Physiol Regul Integr Comp Physiol)
Link: https://pubmed.ncbi.nlm.nih.gov/31483156/

The sauna and body fluid balance (Ahonen & Nousiainen, 1988, Ann Clin Res)
Link: https://pubmed.ncbi.nlm.nih.gov/3218897/

Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver (You & Crabb, 2004, Am J Physiol Gastrointest Liver Physiol)
Link: https://pubmed.ncbi.nlm.nih.gov/15194557/

Alcoholic liver disease (Seitz et al., 2018, Nat Rev Dis Primers)
Link: https://pubmed.ncbi.nlm.nih.gov/30115921/

Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.